Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC-Reference-Cited by-同舟云学术

Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC

Published:2022-08 Issue: Volume: Page:
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Trauner Michael,Bowlus Christopher L.,Gulamhusein Aliya,Hameed Bilal,Caldwell Stephen H.,Shiffman Mitchell L.,Landis Charles,Muir Andrew J.,Billin Andrew,Xu Jun,Liu Xiangyu,Lu Xiaomin,Chung Chuhan,Myers Robert P.,Kowdley Kris V.

Funder

Gilead Sciences Inc

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference25 articles.

1. Primary sclerosing cholangitis;Lazaridis;N Engl J Med,2016

2. Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC?;Chapman;Nat Rev Gastroenterol Hepatol,2010

3. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis;Lindor;Hepatology,2009

4. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study;Olsson;Gastroenterology,2005

5. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial;Beuers;Hepatology,1992

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study;Clinical and Translational Gastroenterology;2024-07-01

2. Sarmentol H derived from Sedum sarmentosum Bunge directly targets FXR to mitigate cholestasis by recruiting SRC-1;Phytomedicine;2024-07

3. Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications;Medical Review;2024-07-01

4. Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis;Expert Opinion on Pharmacotherapy;2024-05-02

5. Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease;Journal of Pharmacology and Experimental Therapeutics;2024-02-26